Trials / Completed
CompletedNCT01048255
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-765 | 300mg Oral Tablet, 900mg TID |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-01-13
- Last updated
- 2014-01-27
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01048255. Inclusion in this directory is not an endorsement.